ADXN
Addex Therapeutics Ltd
NASDAQ: ADXN · HEALTHCARE · BIOTECHNOLOGY
$7.00
+3.86% today
Updated 2026-04-29
Market cap
$8.62M
P/E ratio
—
P/S ratio
54.40x
EPS (TTM)
$-9.17
Dividend yield
—
52W range
$5 – $12
Volume
0.0M
Addex Therapeutics Ltd (ADXN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-1,404.00%
ROE
-72.80%
ROA
-15.90%
Debt/equity
0.01x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $4.74M | $-20.54M | 100.00% | -441.03% | -433.53% |
| 2007 | $486930.00 | $-35.09M | 132.04% | -7,726.28% | -7,205.50% |
| 2008 | $26.81M | $-22.07M | 100.00% | -92.78% | -82.32% |
| 2009 | $4.09M | $-42.69M | 100.00% | -1,052.47% | -1,043.62% |
| 2010 | $1.98M | $-33.65M | -1,477.75% | -1,700.93% | -1,703.33% |
| 2011 | $2.82M | $-31.14M | -891.19% | -1,097.02% | -1,102.95% |
| 2012 | $121089.00 | $-26.61M | -948.14% | -22,306.25% | -21,976.79% |
| 2013 | $91760.00 | $-14.46M | — | -15,756.97% | -15,760.49% |
| 2014 | $85404.00 | $-1.77M | — | -2,103.69% | -2,078.19% |
| 2015 | $40301.00 | $-4.20M | 74.55% | -9,597.64% | -10,432.03% |
| 2016 | $17329.00 | $-3.15M | -2,352.05% | -18,059.88% | -18,174.08% |
| 2017 | $499894.00 | $-3.28M | 94.05% | -647.15% | -656.22% |
| 2018 | $6.04M | $-1.64M | 97.61% | -23.57% | -27.21% |
| 2019 | $2.76M | $-14.78M | 91.67% | -528.59% | -534.98% |
| 2020 | $3.61M | $-12.86M | 100.00% | -338.88% | -355.92% |
| 2021 | $2.92M | $-15.35M | 100.00% | -531.70% | -526.42% |
| 2022 | $1.42M | $-20.80M | 100.00% | -741.04% | -1,462.57% |
| 2023 | $1.61M | $-10.56M | 100.00% | -139.06% | -654.47% |
| 2024 | $404102.00 | $7.06M | 100.00% | -681.82% | 1,746.04% |